Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CervoMed (CRVO) Net Margin (2023 - 2025)

CervoMed's Net Margin history spans 8 years, with the latest figure at 2394.96% for Q3 2025.

  • For Q3 2025, Net Margin fell 214990.0% year-over-year to 2394.96%; the TTM value through Sep 2025 reached 415.21%, down 29654.0%, while the annual FY2024 figure was 167.28%, 6100.0% down from the prior year.
  • Net Margin for Q3 2025 was 2394.96% at CervoMed, down from 355.47% in the prior quarter.
  • Across five years, Net Margin topped out at 70.44% in Q2 2024 and bottomed at 2394.96% in Q3 2025.
  • The 3-year median for Net Margin is 172.13% (2023), against an average of 380.57%.
  • The largest annual shift saw Net Margin skyrocketed 1146bps in 2024 before it plummeted -214990bps in 2025.
  • A 3-year view of Net Margin shows it stood at 94.83% in 2023, then tumbled by -227bps to 310.3% in 2024, then plummeted by -672bps to 2394.96% in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Net Margin are 2394.96% (Q3 2025), 355.47% (Q2 2025), and 255.22% (Q1 2025).